DiaMedica Therapeutics Inc (DMAC) has fallen -9.47% in a Week, Should You Hold?

A rating of 95 puts DiaMedica Therapeutics Inc (DMAC) near the top of the Biotechnology industry according to InvestorsObserver. DiaMedica Therapeutics Inc's score of 95 means it scores higher than 95% of stocks in the industry. DiaMedica Therapeutics Inc also received an overall rating of 73, putting it above 73% of all stocks. Biotechnology is ranked 63 out of the 148 industries.

DMAC has an Overall Score of 73. Find out what this means to you and get the rest of the rankings on DMAC!

See Full DMAC Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 73 would rank higher than 73 percent of all stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With DiaMedica Therapeutics Inc Stock Today?

DiaMedica Therapeutics Inc (DMAC) stock has risen 3.38% while the S&P 500 has fallen -1.04% as of 10:26 AM on Tuesday, Aug 8. DMAC is higher by $0.10 from the previous closing price of $2.96 on volume of 13,040 shares. Over the past year the S&P 500 has risen 8.01% while DMAC is higher by 71.91%. DMAC lost -$0.58 per share the over the last 12 months. Click Here to get the full Stock Report for DiaMedica Therapeutics Inc stock.